The hepatitis C virus enigma

APMIS

Volumn 117, Issue 5-6, 2009, Pages 427-439

  Myrmel, Helge ^a   Ulvestad, Elling ^a,b   Åsjø, Birgitta ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Hepatitis; Immunology; Variability; Virus

Indexed keywords

ALPHA INTERFERON; INTERFERON; PEGINTERFERON; RIBAVIRIN;

ADAPTIVE IMMUNITY; DISEASE COURSE; DRUG POTENTIATION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HOST RESISTANCE; HUMAN; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS CELL INTERACTION;

ANTIGENS, CD; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG SYNERGISM; EVOLUTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LIVER NEOPLASMS; POLYETHYLENE GLYCOLS; RECEPTORS, VIRUS; RIBAVIRIN; T-LYMPHOCYTE SUBSETS; VIRAL HEPATITIS VACCINES; VIREMIA; VIRUS REPLICATION;

EID: 65349153811     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2009.02454.x     Document Type: Review

References (93)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989 244 : 359 64.
2. World Health Organization. Hepatitis C - global prevalence (update). Wkly Epidemiol Rec 1999 74 : 425 6.
3. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999 341 : 556 62.
4. Duberg A, Janzon R, Bäck E, Ekdahl K, Blaxhult A. The epidemiology of hepatitis C virus infection in Sweden. Eur Surveill 2008 13. Available at ArticleId=18882 (accessed May 26, 2008).
5. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002 36 : S35 46.
6. Lerat H, Berby F, Trabaud MA, Vidalin O, Major M, Trépo C, et al. Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J Clin Invest 1996 97 : 845 51.
7. Lamelin JP, Zoulim F, Trépo C. Lymphotropism of hepatitis B and C viruses: an update and a newcomer. Int J Clin Lab Res 1995 25 : 1 6.
8. Bain C, Fatmi A, Zoulim F, Zarski JP, Trépo C, Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001 120 : 512 24.
9. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998 282 : 938 41.
10. Neumann AU, Lam NP, Dahari H, Gretch DR, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998 282 : 103 7.
11. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995 15 : 41 63.
12. Bukh J, Purcell RH, Miller RH. Sequence analysis of the 5′ noncoding region of hepatitis C virus. Proc Natl Acad Sci USA 1992 89 : 4942 6.
13. Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL, et al. The origin of hepatitis C virus genotypes. J Gen Virol 1997 78 : 321 8.
14. Maljkovic Berry I, Ribeiro R, Kothari M, Athreya G, Daniels M, Lee HY, et al. Unequal evolutionary rates in the human immunodeficiency virus type 1 (HIV-1) pandemic: the evolutionary rate of HIV-1 slows down when the epidemic rate increases. J Virol 2007 81 : 10625 35.
15. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
16. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001 7 : 927 33.
17. Katoh M, Tateno C, Yoshizato K, Yokoi T. Chimeric mice with humanized liver. Toxicology 2008 246 : 9 17.
18. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005 309 : 623 6.
19. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA, et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci USA 2006 103 : 3805 9.
20. Aly HH, Watashi K, Hijikata M, Kaneko H, Takada Y, Egawa H, et al. Serum-derived hepatitis C virus infectivity in interferon regulatory factor-7-suppressed human primary hepatocytes. J Hepatol 2007 46 : 26 36.
21. Buck M. Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. PLoS ONE 2008 3 : e2660 doi :.
22. Helle F, Dubuisson J. Hepatitis C virus entry into host cells. Cell Mol Life Sci 2008 65 : 100 12.
23. Kawai T, Akira S. Toll-like receptor downstream signaling. Arthr Res Ther 2005 7 : 12 9.
24. Parker DC. T cell-dependent B cell activation. Annu Rev Immunol 1993 11 : 331 60.
25. Mosmann TR, Coffmann RL. TH1 and TH2 cells: different pattern of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989 7 : 145 73.
26. Boes M, Cerny J, Massol R, Op den Brouw M, Kirchhausen T, Chen J, et al. T cell engagement of dendritic cells rapidly rearranges MHC class II transport. Nature 2002 418 : 983 8.
27. Sato A, Iwasaki A. Induction of antiviral immunity requires toll-like receptor signaling in both stromal and dendritic cell compartments. Proc Natl Acad Sci USA 2004 101 : 16274 9.
28. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 2006 43 : S54 62.
29. Ulvestad E. Defending Life. The Nature of Host-Parasite Relations. Dordrecht : Springer, 2007.
30. Mathai J, Shimoda K, Banner BF, Mori M, Bonkovsky HL, Barnard GF. IFN-alpha receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy. J Interferon Cytokine Res 1999 19 : 1011 8.
31. Foy E, Li K, Wang C, Sumpter R Jr., Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003 300 : 1145 8.
32. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002 195 : 43 50.
33. Chen M, Sallberg M, Sonnerborg A, Weiland O, Mattson L, Jin L, et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology 1999 116 : 135 43.
34. Page-Shafer K, Pappalardo BL, Tobler LH, Phelps BH, Edlin BR, Moss AR, et al. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol 2008 46 : 499 506.
35. Yu MY, Bartosch B, Zhang P, Guo Z, Renzi PM, Shen L, et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci USA 2004 101 : 7705 10.
36. Vanwolleghem T, Bukh J, Meuleman P, Desombere I, Meunier JC, Alter H, et al. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology 2008 47 : 1846 55.
37. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000 288 : 339 44.
38. Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004 189 : 1846 55.
39. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 2006 12 : 6756 65.
40. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000 191 : 1499 512.
41. Thimme R, Oldach D, Chang K-M, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001 194 : 1395 406.
42. Haynes NM. Follicular associated T cells and their B-cell helper qualities. Tissue Antigens 2008 71 : 97 104.
43. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999 117 : 933 41.
44. + T-cell epitope within nonstructural protein 3 in acute hepatitis C infection. J Virol 1997 71 : 6011 9.
45. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997 25 : 449 58.
46. Woitas RP, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 1997 159 : 1012 8.
47. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996 98 : 706 14.
48. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R. T cell response in hepatitis C virus infection. J Clin Virol 2005 32 : 75 85.
49. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003 37 : 60 4.
50. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006 13 : 34 41.
51. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung M-C, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003 125 : 80 8.
52. Larghi A, Zuin M, Crosignani A, Ribero ML, Pipia C, Battezzati PM, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology 2002 36 : 993 1000.
53. Semmo N, Barnes E, Taylor C, Kurtz J, Harcourt G, Smith N, et al. T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Lancet 2005 365 : 327 9.
54. Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N, et al. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 1998 158 : 177 81.
55. + T-cell response in acute hepatitis C primary infection and reinfection. J Clin Virol 2006 36 : 24 31.
56. Sarasin-Filipowicz M, Oakeley EJ, Duong FHT, Christen V, Terracciano L, Filipowicz W, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008 105 : 7034 9.
57. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008 89 : 1 47.
58. Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002 14 : 432 6.
59. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001 14 : 461 70.
60. Ulvestad E, Aarseth JH, Vedeler C, Nyland H, Myhr K-M. The effects of interferon-α2a on concentrations of immunoglobulins, complement and lymphocytes in patients with multiple sclerosis. Scand J Immunol 2004 59 : 103 8.
61. Rizza P, Capone I, Urbani F, Montefiore E, Rapicetta M, Chionne P, et al. Evaluation of the effects of human leukocyte IFN-α on the immune response to the HBV vaccine in healthy unvaccinated individuals. Vaccine 2008 26 : 1038 49.
62. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996 25 : 591 8.
63. Bodenheimer HC Jr., Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997 26 : 473 7.
64. Rigopoulou EI, Abbott WG, Williams R, Naoumov NV. Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. Antiviral Res 2007 75 : 36 42.
65. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000 118 : 346 55.
66. Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998 79 : 2381 91.
67. Picardi A, Gentilucci UV, Zardi EM, D'Avola D, Amoroso A, Afeltra A. The role of ribavirin in the combination therapy of hepatitis C virus infection. Curr Pharma Des 2004 10 : 2081 92.
68. Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, Mossman TR, et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988 334 : 255 8.
69. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998 339 : 1485 92.
70. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998 352 : 1426 32.
71. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000 343 : 1666 72.
72. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000 343 : 1673 80.
73. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 65.
74. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
75. Moriishi K, Matsuura Y. Evaluation systems for anti-HCV drugs. Adv Drug Deliv Rev 2007 59 : 1213 21.
76. Pawlotsky J-M, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007 132 : 1979 98.
77. Njoroge FG, Chen KX, Shih NY, Piwinski JJ. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res 2008 41 : 50 9.
78. Koev G, Kati W. The emerging field of HCV drug resistance. Expert Opin Investig Drugs 2008 17 : 303 19.
79. Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 2001 33 : 1479 87.
80. Major ME, Mihalik K, Puig M, Rehermann B, Nascimbeni M, Rice CM, et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 2002 76 : 6586 95.
81. Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, et al. Cross-genotype immunity to hepatitis C virus. J Virol 2004 78 : 1575 81.
82. Bukh J, Thimme R, Meunier JC, Faulk K, Spangenberg HC, Chang KM, et al. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol 2008 82 : 8183 95.
83. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet 2002 359 : 1478 83.
84. Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 2008 48 : 1746 52.
85. Meuleman P, Leroux-Roels G. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Res 2008 80 : 231 8.
86. Zhang XX, Zhang SY, Liu J, Lu ZM, Wang Y. Expression of hepatitis C virus hypervariable region 1 and its clinical significance. World J Gastroenterol 2003 9 : 1003 7.
87. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007 132 : 667 78.
88. Mikkelsen M, Bukh J. Current status of a hepatitis C vaccine: encouraging results but significant challenges ahead. Curr Infect Dis Rep 2007 9 : 94 101.
89. Strickland GT, El-Kamary SS, Klenerman P, Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect Dis 2008 8 : 379 86.
90. Burioni R, Perotti M, Mancini N, Clementi M. Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs. J Hepatol 2008 49 : 299 300.
91. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008 14 : 25 7.
92. Eren R, Landstein D, Terkieltaub D, Nussbaum O, Zauberman A, Ben-Porath J, et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 2006 80 : 2654 64.
93. Owsianka AM, Tarr AW, Keck ZY, Li TK, Witteveldt J, Adair R, et al. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol 2008 89 : 653 9.